公开(公告)号：US20210122830A1

公开(公告)日：2021-04-29

申请号：US17003442

申请日：2020-08-26

Applicant: GENMAB A/S

Inventor： Bart DE GOEIJ ,  Edward N. VAN DEN BRINK ,  Simone DE HAIJ ,  Thilo RIEDL ,  Rene HOET ,  Ole BAADSGAARD, D.M.Sc. ,  David SATIJN ,  Jan VAN DE WINKEL ,  Paul PARREN

IPC: C07K16/30 ,  C07K16/32

Abstract: Isolated monoclonal antibodies which bind to human epidermal growth factor receptor 2 (HER2), and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.

公开(公告)号：US20210107985A1

公开(公告)日：2021-04-15

申请号：US16883333

申请日：2020-05-26

Applicant: GENMAB A/S

Inventor： Janine SCHUURMAN ,  Catharina Emanuele Gerarda HAVENITH ,  Paul PARREN ,  Jan G. J. VAN DE WINKEL ,  Denise Leah WILLIAMS ,  Jørgen PETERSEN ,  Ole BAADSGAARD

IPC: C07K16/28 ,  G01N33/68 ,  A61K39/395 ,  A61K45/06 ,  A61N5/06 ,  C07K16/42 ,  C07K16/46 ,  G01N33/574 ,  G01N33/569

Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD25, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a hybridoma, a transfectoma or in a nonhuman transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, nonhuman transgenic animals, hybridomas and transfectomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

公开(公告)号：US10906991B2

公开(公告)日：2021-02-02

申请号：US14934956

申请日：2015-11-06

Applicant: GENMAB A/S

Inventor： Janine Schuurman ,  Tom Vink ,  Jan Van De Winkel ,  Aran Frank Labrijn ,  Rob Aalberse ,  Marijn Van Der Neut Kolfschote ,  Paul Parren

IPC: C07K16/46 ,  C07K16/00 ,  C07K16/28

Abstract: The invention relates to an ex vivo method for the generation of a bispecific antibody, comprising the steps of: a) providing a first antibody having a first binding specificity, wherein said first antibody comprises an IgG4-like CH3 region, b) providing a second antibody having a second binding specificity which differs from said first binding specificity, wherein said second antibody comprises an IgG4-like CH3 region, c) incubating said first and second antibodies together under reducing conditions which allow the cysteines in the core hinge region to undergo disulfide-bond isomerization, and d) obtaining a bispecific antibody. The invention furthermore relates to bispecific antibodies obtainable by the method of the invention.

公开(公告)号：US10457735B2

公开(公告)日：2019-10-29

申请号：US15538419

申请日：2016-01-08

Applicant: BIONTECH AG ,  GENMAB A/S

Inventor： Ugur Sahin ,  Friederike Gieseke ,  Isil Altintas ,  David Satijn ,  Paul Parren

IPC: C07K16/28

Abstract: The present invention relates to binding agents binding to receptors of the TNF superfamily, in particular binding agents binding to at least two different receptors of the TNF superfamily, as well as to their use in medicine. The present invention further relates to nucleic acid molecules encoding such binding agents, to cells comprising such nucleic acid molecules and to pharmaceutical compositions and kits.

公开(公告)号：US20170327597A1

公开(公告)日：2017-11-16

申请号：US15536143

申请日：2015-12-18

Applicant: GENMAB A/S

Inventor： Aran F. LABRIJN ,  Joyce I. MEESTERS ,  Janine SCHUURMAN ,  Paul PARREN ,  Anthony ARMSTRONG ,  Matthew BUNCE ,  Mark CHIU ,  Thomas NESSPOR ,  Adam ZWOLAK

IPC: C07K16/46 ,  C07K16/40 ,  A61K49/00 ,  C07K16/28

CPC classification number: C07K16/462 ,  A61K49/0008 ,  C07K16/00 ,  C07K16/2809 ,  C07K16/32 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/526 ,  C07K2317/64 ,  C07K2317/73

Abstract: Novel rodent bispecific heterodimeric proteins, such as rodent bispecific antibodies, in vitro method for producing such, and uses thereof.

公开(公告)号：US20150376282A1

公开(公告)日：2015-12-31

申请号：US14739768

申请日：2015-06-15

Applicant: Genmab A/S

Inventor： Aran Frank Labrijn ,  Stefan Loverix ,  Paul Parren ,  Jan Van De Winkel ,  Janine Schuurman ,  Ignace Laster

IPC: C07K16/28 ,  A61K47/48 ,  A61K51/10 ,  A61K39/395

CPC classification number: C07K16/2863 ,  A61K39/3955 ,  A61K47/6849 ,  A61K51/103 ,  A61K2039/505 ,  C07K16/00 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/76

Abstract: The present invention relates to positions in the constant region of antibodies, in particular the CH3 region of IgG4, which affect the strength of CH3-CH3 interactions. Mutations that either stabilize or destabilize this interaction are disclosed.

Abstract translation: 本发明涉及抗体的恒定区，特别是IgG4的CH3区的位置，其影响了CH3-CH3相互作用的强度。 公开了稳定或不稳定这种相互作用的突变。

公开(公告)号：US09181344B2

公开(公告)日：2015-11-10

申请号：US12096196

申请日：2006-12-15

Applicant: Mario Losen ,  Pilar Martinez-Martinez ,  Marc H. De Baets ,  Yvo Graus ,  Janine Schuurman ,  Paul Parren

Inventor： Mario Losen ,  Pilar Martinez-Martinez ,  Marc H. De Baets ,  Yvo Graus ,  Janine Schuurman ,  Paul Parren

IPC: C07K16/28 ,  A61K39/00

CPC classification number: C07K16/286 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/71

Abstract: The invention relates to the treatment of autoimmune diseases and disorders, in particular myasthenia gravis, by administration of effector-function-deficient antibodies, wherein said effector-function-deficient antibodies are capable of competing with one or more of the auto-antibodies involved in mediating the antibody-mediated auto-immune disease or disorder for binding to a target auto-antigen.

Abstract translation: 本发明涉及通过施用效应子功能缺陷型抗体治疗自身免疫性疾病和病症，特别是重症肌无力，其中所述效应子功能缺陷型抗体能够与参与的一种或多种自身抗体竞争 介导抗体介导的自身免疫疾病或病症以结合靶标自身抗原。

公开(公告)号：US20140093454A1

公开(公告)日：2014-04-03

申请号：US13964956

申请日：2013-08-12

Applicant: Genmab A/S

Inventor： Jessica Teeling ,  Sigrid Ruuls ,  Martin Glennie ,  Jan G.J. van de Winkel ,  Paul Parren ,  Jørgen Petersen ,  Ole Baadsgaard ,  Haichun Huang

IPC: C07K16/28 ,  A61K45/06 ,  G01N33/68 ,  A61K39/395

CPC classification number: C07K16/2887 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/4258 ,  C07K2317/21 ,  C07K2317/54 ,  C07K2317/56 ,  C07K2317/72 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/92 ,  G01N33/686

Abstract: Isolated human monoclonal antibodies which bind to and inhibit human CD20, and related antibody-based compositions and molecules, are disclosed. The human antibodies can be produced by a transfectoma or in a non-human transgenic animal, e.g., a transgenic mouse, capable of producing multiple isotypes of human monoclonal antibodies by undergoing V-D-J recombination and isotype switching. Also disclosed are pharmaceutical compositions comprising the human antibodies, non-human transgenic animals and hybridomas which produce the human antibodies, and therapeutic and diagnostic methods for using the human antibodies.

Abstract translation: 公开了结合并抑制人CD20的分离的人单克隆抗体以及相关的基于抗体的组合物和分子。 人抗体可以通过经历V-D-J重组和同种型转换能够产生人单克隆抗体多重同种型的转染瘤或非人转基因动物例如转基因小鼠产生。 还公开了包含人抗体，非人转基因动物和产生人抗体的杂交瘤的药物组合物，以及使用人抗体的治疗和诊断方法。

公开(公告)号：US20140030273A1

公开(公告)日：2014-01-30

申请号：US13982959

申请日：2012-02-01

Applicant: Sandra Verploegen ,  Marije Overdijk ,  Riemke Van Dijkhuizen ,  Willem Karel Bleeker ,  Patrick Van Berkel ,  Paul Parren ,  Steen Lisby

Inventor： Sandra Verploegen ,  Marije Overdijk ,  Riemke Van Dijkhuizen ,  Willem Karel Bleeker ,  Patrick Van Berkel ,  Paul Parren ,  Steen Lisby

IPC: C07K16/18 ,  A61K45/06 ,  A61K38/19 ,  A61K35/76 ,  A61K38/16 ,  A61K35/14 ,  A61K39/395 ,  A61K31/7088

CPC classification number: A61K39/39541 ,  A61K31/7088 ,  A61K35/17 ,  A61K35/76 ,  A61K38/162 ,  A61K38/19 ,  A61K39/39533 ,  A61K39/39566 ,  A61K45/06 ,  A61K47/6849 ,  A61K51/1027 ,  A61K2039/505 ,  A61K2121/00 ,  C07K16/18 ,  C07K16/2833 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/73 ,  C07K2317/77 ,  C07K2317/92 ,  Y02A50/472

Abstract: Isolated human monoclonal antibodies which bind to human CD74 and related antibody-drug conjugates are disclosed. Pharmaceutical compositions comprising the antibodies or antibody-drug conjugates, and therapeutic and diagnostic methods for using the antibodies and/or antibody-drug conjugates, are also disclosed.

Abstract translation: 公开了与人CD74和相关抗体 - 药物偶联物结合的分离的人单克隆抗体。 还公开了包含抗体或抗体 - 药物偶联物的药物组合物，以及使用抗体和/或抗体 - 药物偶联物的治疗和诊断方法。

公开(公告)号：US20130216548A1

公开(公告)日：2013-08-22

申请号：US13583743

申请日：2011-03-10

Applicant: Joost J. Neijssen ,  Bart De Goeij ,  Edward Norbert Van Den Brink ,  Aran Frank Labrijn ,  Rene Hoet ,  Janine Schuurman ,  Paul Parren ,  Jan Van De Winkel

Inventor： Joost J. Neijssen ,  Bart De Goeij ,  Edward Norbert Van Den Brink ,  Aran Frank Labrijn ,  Rene Hoet ,  Janine Schuurman ,  Paul Parren ,  Jan Van De Winkel

IPC: C07K16/40 ,  A61K45/06 ,  A61K39/395

CPC classification number: C07K16/3076 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/2863 ,  C07K16/40 ,  C07K2317/21 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/524 ,  C07K2317/526 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2317/71 ,  C07K2317/74 ,  C07K2317/76 ,  C07K2317/92 ,  G01N33/5748 ,  G01N2333/912

Abstract: Isolated monoclonal antibodies which bind to human c-Met, the hepatocyte growth factor receptor, and related antibody-based compositions and molecules, are disclosed. Pharmaceutical compositions comprising the antibodies and therapeutic and diagnostic methods for using the antibodies are also disclosed.